No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study - Wikidata - wikimedia - TriplyDB

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

http://www.wikidata.org/entity/Q36610368

about

Ovarian cancer screening--current status, future directions Salpingectomy as a means to reduce ovarian cancer risk Understanding the needs of women considering risk-reducing salpingo-oophorectomy.The preclinical natural history of serous ovarian cancer: defining the target for early detection Two decades after BRCA: setting paradigms in personalized cancer care and prevention DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct.Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort.Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome.Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity.Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing Genomic Biomarkers for Breast Cancer Risk.Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.

P2860

Q27004471-EE38BFDD-458F-4F24-A646-78DFE64B5460 Q27011949-1EE2514A-4064-4D30-96FD-3286BFA347C4 Q30419497-D59E9F97-5EFC-4B0C-AE4A-54AD2662373B Q33487678-8DE14204-7108-4CDD-A92D-A87194A5AED4 Q33820594-21E2A325-6B8D-4F89-A5BE-983262FFE698 Q34262449-2F3B166D-D365-4513-BCD6-B17C81CC4B64 Q34327275-68F06BCA-FD02-4EDE-89EE-6BCBBB9F803E Q35108393-3B745F2F-7988-4C95-94DB-DC9A36E800BF Q35540547-09FC2382-371A-45D4-938F-F31B339A85E6 Q35596203-080DA5EC-BE13-4D58-A74A-EB8DB4145C42 Q35749439-70C2E808-113B-455A-A0BF-7927311FD3AA Q36039369-B53B6155-802B-4DCE-AF50-37E345C5E4F6 Q36218446-0802CD7D-9E9F-4544-A00B-0C6817BF77CC Q36240959-D2F64307-7F19-4FE6-BFD7-4A798DAFC289 Q36313479-52BF202D-1E9B-4EA4-8B45-DB8B6C6DDC5F Q36392688-2AFC81B3-0F18-4CB6-90A4-908447806410 Q36490048-1CC1AA93-3579-40E5-B2A0-88BCF8CF0DD7 Q36906183-5D0F4F7C-D631-47F0-A159-9FF339CB0478 Q37081960-2ED8DC53-9721-440C-AE16-039B2997B25E Q37090813-7A54E99B-08DD-49DE-BCFF-61BC73D39851 Q37185670-3C676263-6BDD-47F0-AD44-5138E486160A Q37242239-0B1C5D3E-72F5-45F7-BFE9-4975CD5F817C Q37407195-4A395EA7-503B-43BA-AA9E-D5944485F876 Q47958061-9DE137A6-D789-473D-A4CA-70B6D64A2F36

P2860

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

http://www.wikidata.org/entity/Q36610368

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

No efficacy of annual gynaecol ...... observational follow-up study

@ast

No efficacy of annual gynaecol ...... observational follow-up study

@en

type

label

No efficacy of annual gynaecol ...... observational follow-up study

@ast

No efficacy of annual gynaecol ...... observational follow-up study

@en

prefLabel

No efficacy of annual gynaecol ...... observational follow-up study

@ast

No efficacy of annual gynaecol ...... observational follow-up study

@en

P1433

Q36610368-4B831A43-F231-4989-9E61-C87195377C62

P1476

Q36610368-FAABE7C0-A85C-439F-91F6-A40BDAD95EEC

P2093

Q36610368-106637EC-3FCA-4F95-BF9A-D887BA617BCE

Q36610368-2C2D0419-2363-43B8-AB40-4AB4D108C17C

Q36610368-4B2C5F19-ADC5-4C65-82C0-06DDF8057194

Q36610368-8059387D-B357-40C5-BFBA-4F17D20A3C1B

Q36610368-8C431B5F-4466-47BF-A6B9-CFD3E9EFE5DB

Q36610368-A16DA1BE-CB0F-4065-800B-760E57D24F91

Q36610368-A593E229-5B9F-4369-B65C-203D63D4F8B0

Q36610368-C4C4A76D-C5EF-49E1-99B7-39C4B37B9CB6

Q36610368-D637B04C-FBD0-40AD-A0A4-E5D954D235DD

Q36610368-E22F5C68-C603-4D87-80A9-0C71EE0662F6

P2860

Q36610368-103953E7-F4F9-489A-B309-3D55B1694F9F

Q36610368-1EAC3CC1-35F2-497D-9FB6-E6BC213180D8

Q36610368-29208582-8EB3-435A-AAA2-1D6BD57BD64B

Q36610368-2E1446A6-B420-4BE0-B58E-9B5C9BACE51E

Q36610368-2FEE0CA7-2224-4E34-B3E2-F609D5348F3E

Q36610368-5066E7DE-8C3A-4489-83ED-AEF54DB7605A

Q36610368-5172623A-3E42-40F1-9504-02E21BA27A1B

Q36610368-5F478024-542D-443D-8E3C-A28BE4858C6C

Q36610368-60408EB7-1F26-4B61-8340-F700C672511C

Q36610368-65BFD9FE-8214-41F1-BDD8-9CA0A1635806

P2888

Q36610368-0ADA6FD8-9AE7-4503-826E-D71DA92B658F

P304

Q36610368-8CC00F83-4C6F-4E2A-BAD7-FC54651A54E1

P31

Q36610368-F0ED9BBD-64FA-48F0-BF6D-98E359F94A41

P356

Q36610368-FA64DE02-5996-4428-BB66-C48AB9E8E8BA

P407

Q36610368-B929D40A-6018-4A04-B282-7E18560FE899

P433

Q36610368-25E2DFBC-036F-4B3A-AB27-EDD931CCB6E6

P478

Q36610368-425F3FF8-98BC-40A4-9C62-D8C07B3590F1

P577

Q36610368-55BB6F95-86F1-4353-98DD-F5CE8EF12DF4

P5875

Q36610368-9ED76DF9-D6B1-43DD-8707-5881F69E828F

P6179

Q36610368-63396E23-A11A-4400-A1FB-F277C208A195

P698

Q36610368-7CA2F4EE-0A4A-42CE-B7BE-F04801022403

P932

Q36610368-7EA5ECE6-A271-4F37-8D65-46DE26E62307

P356

P1433

British Journal of Cancer

P1476

No efficacy of annual gynaecol ...... observational follow-up study

@en

P2093

B B J Hermsen

http://www.w3.org/2001/XMLSchema#string

C T Brekelmans

http://www.w3.org/2001/XMLSchema#string

C W Burger

http://www.w3.org/2001/XMLSchema#string

G H de Bock

http://www.w3.org/2001/XMLSchema#string

H H van Boven

http://www.w3.org/2001/XMLSchema#string

J A de Hullu

http://www.w3.org/2001/XMLSchema#string

K N Gaarenstroom

http://www.w3.org/2001/XMLSchema#string

L F Massuger

http://www.w3.org/2001/XMLSchema#string

M A Rookus

http://www.w3.org/2001/XMLSchema#string

M J Mourits

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

Serum protein markers for early detection of ovarian cancer

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.

Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.

Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.

P2888

P304

1335-1342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603725

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51390836

http://www.w3.org/2001/XMLSchema#string

P6179

1001145193

http://www.w3.org/2001/XMLSchema#string

P698

17426707

http://www.w3.org/2001/XMLSchema#string

P932

2360170

http://www.w3.org/2001/XMLSchema#string